看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
/ P5 W. O" e* W. R, D3 l( r+ C/ w2 [
# Y: ~+ T9 p9 T5 |9 m
6 H1 l: n6 A" i$ |7 FCurrently available feasibility data for possible combination strategies. ( e0 f* J1 O8 x% k: z! y! m+ O
————————————————————————————————2 T: t! D7 M6 k$ M; [! @- w
Combination Feasibility according to preliminary data # ^/ x2 v, D |) `3 f2 T
——————————————————————————————————7 e* D( U6 Z& U5 W. ?3 k0 N% e3 M
Bevacizumab + sorafenib Yes, reduced dose 3 o/ n. ~, S% K, t+ g& E
Bevacizumab + sunitinib† No * m( X- X' Y l1 y6 O
Bevacizumab + temsirolimus Yes ; p, w( ?- Y, f5 u f
Bevacizumab + everolimus Yes ; P/ h$ k$ v+ ]
Sorafenib + sunitinib ? 3 L1 \! d4 J# p$ O
Sorafenib + temsirolimus Yes, reduced dose # g0 V7 z# ] j) w, W
Sorafenib + everolimus Yes, reduced dose
1 [, X5 u, Y; y; wSunitinib + temsirolimus† No 0 i$ @2 W4 V A: w; R) n
Sunitinib + everolimus ? 3 h2 X' s0 I8 Q" c4 F" _$ r) A
Temsirolimus + everolimus ?
- \# J# H/ d3 Q————————————————————
/ [3 w( z; U8 X7 D3 D/ C" e†Led to US FDA warning.
0 m# s7 R( O& y L?: As yet unattempted combination.1 S0 {$ I/ }/ h/ r7 r
|
显身卡
